Ultragenyx Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Novato CA United States (2010)

Organization Overview

First Clinical Trial
2010
NCT00947960
First Marketed Drug
2017
vestronidase alfa-vjbk (mepsevii)
First NDA Approval
2017
vestronidase alfa-vjbk (mepsevii)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ultragenyx Pharmaceutical | Ultragenyx Pharmaceutical Inc | ULTRAGENYX PHARM INC